D-1103-2020 Class II Terminated
FDA drug recall D-1103-2020 was initiated by Avet Pharmaceuticals, Inc. on Mar 26, 2020 and is designated Class II. Reason for recall: CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level The recall status is terminated (terminated Mar 8, 2021). Affected quantity: a) 2,904; b) 14,316; c) 1,368 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Apr 15, 2020
- Initiation Date
- Mar 26, 2020
- Termination Date
- Mar 8, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- a) 2,904; b) 14,316; c) 1,368 bottles
Product description
Losartan Potassium Tablets USP 50 mg, a) 30 count (NDC 23155-645-03), b) 90 count (NDC 23155-645-09) and c) 1000 count (NDC 23155-645-10) bottles, Rx only, Manufactured by: Vivimed Life Sciences Private Limited, Tamil Nadu, India, Manufactured for: Heritage Pharmaceutical Inc., East Brunswick, NJ 08816 NDC 23155-645-09
Reason for recall
CGMP Deviations: FDA lab confirmed presence of an impurity, N-Methylnitrosobutyric acid (NMBA) in the finished product above the interim acceptable daily intake level
Distribution pattern
Nationwide
Code information
a) CL018008A, exp Mar 2020; b) CL018008B, exp Mar 2020; c) CL018009A, exp Mar 2020
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-1103-2020
- openFDA file date
- Nov 16, 2026
- Loaded by RegDataLab
- Nov 17, 2026